ArticleDiabetic medicine : a journal of the British Diabetic Association2026
Detection of prediabetes and undiagnosed type 2 diabetes in underserved communities using community pharmacy point-of-care testing: A prospective feasibility study.
Article in Diabetic medicine : a journal of the British Diabetic Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsEarly detection of type 2 diabetes (T2D) and prediabetes is critical to reduce disease burden, yet disadvantaged populations often remain undiagnosed. We assessed a pharmacy-based pathway using verified point-of-care HbA1c testing to identify prediabetes and enable engagement with a digital prevention programme and established the detection rates for undiagnosed T2D.
methodsWe conducted a prospective feasibility study across 16 community pharmacies in NHS Tayside, Scotland (Feb 2024-Jan 2025). Adults at high risk of T2D, identified using the Diabetes UK 'Know Your Risk' tool, were offered HbA1c testing. Participants with HbA1c 42-47 mmol/mol (6.0-6.4%) were referred directly to a digital diabetes prevention programme (DDP); those with HbA1c ≥48 mmol/mol (6.5%) were advised to attend their GP. Comparator data were drawn from GP patients identified for engagement with the same DPP.
resultsOf 499 pharmacy participants, 75 (15%) had prediabetes; 38 (51%) enrolled in DPP. Nineteen (4%) had HbA1c ≥48 mmol/mol (6.5%); 17 attended GP. Compared with GP-identified prediabetes (951 patients; 212 enrolled, 32%), pharmacy-based recruitment doubled DDP engagement (RR 2.08, 95% CI 1.61-2.67). Pharmacy recruited relatively younger participants from more deprived backgrounds (63% SIMD 1-2 vs. 33% in GP cohort).
conclusionCommunity pharmacies provided effective, equitable access to HbA1c testing and diabetes prevention, identifying individuals with prediabetes and undiagnosed T2D being missed by current pathways and doubling engagement of this underserved population with DPP. Pharmacy-based screening offers a scalable opportunity to reduce health inequalities and expand primary care capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.